Product Description
Lanreotide autogel is a synthetic somatostatin analogue which has been FDA and EMA approved for unresectable, well to moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumor. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30582380/)
Mechanisms of Action: SSTR Agonist, GHR Antagonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Morocco | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Ipsen
Company Location:
Company Founding Year: 1929
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, China, United States
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Gastroenteropancreatic Neuroendocrine Tumor|Neuroendocrine Tumors
Phase 2: Paraganglioma|Pheochromocytoma
Phase 1: Acromegaly|Type 2 Diabetes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ACTRN12624000390583 |
ACTRN12624000390583 | P1 |
Completed |
Acromegaly |
2024-07-05 |
2026-02-15 |
Treatments |
|
NCT03946527 |
LAMPARA | P2 |
Active, not recruiting |
Paraganglioma|Pheochromocytoma |
2027-03-01 |
12% |
2026-03-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
CTR20210552 |
CTR20210552 | P3 |
Completed |
Gastroenteropancreatic Neuroendocrine Tumor|Neuroendocrine Tumors |
2023-01-13 |
2025-04-29 |
Patient Enrollment|Treatments |
|
ACTRN12620001261909 |
ACTRN12620001261909 | P1 |
Recruiting |
Acromegaly |
2021-06-18 |
2026-02-15 |
Treatments |
|
ACTRN12621000800820p |
2006-7041-83/hah | P1 |
Not yet recruiting |
Type 2 Diabetes |
None |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/13/2025 |
News Article |
PANTHERx® Rare Selected by Chiesi for the Distribution of MYCAPSSA® |
|
06/18/2025 |
News Article |
Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients |
|
05/15/2025 |
News Article |
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025 |
|
04/25/2025 |
News Article |
CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU |